Trial record 1 of 1 for:
aim2cerv
Study of ADXS11-001 in Participants With High Risk Locally Advanced Cervical Cancer (AIM2CERV)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02853604 |
|
Recruitment Status :
Terminated
First Posted : August 3, 2016
Results First Posted : March 14, 2023
Last Update Posted : March 14, 2023
|
Sponsor:
Advaxis, Inc.
Collaborator:
Gynecologic Oncology Group
Information provided by (Responsible Party):
Advaxis, Inc.
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
Locally advanced cervical cancer at higher risk for recurrence (HRLACC) following concurrent chemotherapy and radiation therapy. This is a group of participants with a significant unmet need. The estimated probability of disease recurrence or death within 4 years of diagnosis is 50% and the prognosis is very grave for those who experience a recurrence.
The purpose of the study was to compare the disease free survival (DFS) of ADXS11-001 to placebo administered following cisplatin-based combination chemotherapy and radiation (CCRT) with curative intent in participants with HRLACC.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| High Risk Cervical Cancer Advanced Cervical Cancer | Drug: ADXS11-001 Drug: Placebo | Phase 3 |
This was a double-blind, placebo-controlled randomized study of ADXS11-001 administered in the adjuvant setting after completion of CCRT in participants with HRLACC, or death. All eligible participants had received CCRT administered with curative intent according to institutional/national guidelines as well as meeting the minimum standards defined in the protocol. Participants initiated the Screening period within 10 weeks after the completion of CCRT. Baseline radiographic assessments and clinical laboratory assessments were completed no longer than 28 days prior to and 3 days prior to the first study treatment infusion, respectively. Eligible participants were randomized 1:2 to receive either placebo or ADXS11-001. Participants received 1 infusion of study treatment administered every 3 weeks for 3 doses for the first 3 months. Thereafter, participants received study treatment every 8 weeks for a total of 5 doses or until disease recurrence. Participants received a 7-day course of an oral antibiotic or placebo starting 72 hours following the completion of study treatment administration.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 110 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV |
| Actual Study Start Date : | December 15, 2015 |
| Actual Primary Completion Date : | July 31, 2019 |
| Actual Study Completion Date : | July 31, 2019 |
Resource links provided by the National Library of Medicine
MedlinePlus related topics:
Cervical Cancer
| Arm | Intervention/treatment |
|---|---|
|
Placebo Comparator: Placebo
Participants with locally advanced cervical cancer at higher risk for recurrence (HRLACC) received ADXS11-001 matching placebo by intravenous infusion for approximately 60 minutes every 3 weeks for 3 doses (Weeks 1, 4 and 7) and thereafter, every 8 weeks for 5 doses (Weeks 15, 23, 31, 39, and 47) during treatment phase or until disease recurrence. Participants received a 7-day course placebo matching to either trimethoprim/sulfamethoxazole or ampicillin starting 72 hours post treatment in prime and maintenance phase.
|
Drug: Placebo |
|
Experimental: ADXS11-001
Participants with HRLACC received ADXS11-001 at a dose of 1x10^9 colony forming units (CFU) by intravenous infusion for approximately 60 minutes every 3 weeks for 3 doses (Weeks 1, 4 and 7) and thereafter, every 8 weeks for 5 doses (Weeks 15, 23, 31, 39, and 47) during treatment phase or until disease recurrence. Participants received a 7-day course of either trimethoprim/sulfamethoxazole or ampicillin starting 72 hours post treatment in prime and maintenance phase.
|
Drug: ADXS11-001 |
Primary Outcome Measures :
- Disease Free Survival (DFS) [ Time Frame: From the time of randomization to recurrence or death (Maximum duration: 44.7 months) ]DFS was defined as the time from randomization until death or recurrence. The date of recurrence was defined as the date of the first time point when recurrence of disease was determined. The determination of recurrence should occur by definitive pathologic tissue confirmation (e.g., biopsy/fine needle aspirate). However, in those cases where it was not medically feasible to obtain a tissue sample then radiographic evidence, when confirmed by independent radiology review, was used to determine recurrence.
Secondary Outcome Measures :
- Number of Participants With Treatment Emergent Adverse Events [ Time Frame: From first dose of study drug until end of study (Up to 44.7 months) ]Adverse event (AE): any untoward medical occurrence in a participant administered a study treatment & which did not necessarily have to have a causal relationship with the study treatment. An AE is, any unfavorable & unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a pre-existing condition that was temporally associated with the use of study treatment. AE with onset dates on or after the first dose of study treatment were considered treatment emergent.
- Overall Survival (OS) [ Time Frame: From the date of randomization until death due to any cause (Maximum duration: 44.7 months) ]Overall survival was defined as the time from the date of randomization until death due to any cause.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Participants must have a biopsy confirmed diagnosis of squamous cell, adenocarcinoma, or adenosquamous carcinoma of the cervix. Histologic confirmation of the original primary tumor is required.
- Participants with HRLACC.
- Participants included those with stage IB2, IIA2, IIB with pelvic lymph node metastases; all FIGO Stage IIIA, IIIB, IVA or any FIGO Stage (except stage IVB) with para-aortic lymph node metastases as defined by the FIGO 2014 staging criteria for carcinoma of the cervix uteri.
- Participants must have received definitive therapy with curative intent, which consist of at least 4 weeks of treatment with cisplatin and a minimum of 40Gy external beam radiation therapy (EBRT).
- Have performance status of 0 or 1 on the gynaecologic Oncology Group (GOG) performance scale
- Demonstrate adequate organ function
Exclusion Criteria:
- Has not achieved disease-free status after completion of CCRT administered with curative intent.
- Has International Federation of Gynecology and Obstetrics (FIGO) Stage IVB
- Has histologies other than squamous cell, adenocarcinoma, or adenosquamous carcinoma of the cervix.
- Has implanted medical device(s) that pose a high risk for colonization and/or cannot be easily removed (e.g., prosthetic joints, artificial heart valves, pacemakers, orthopedic screw(s), metal plate(s), bone graft(s), or other exogenous implant(s)).
- Has a contraindication (sensitivity or allergy) to trimethoprim/sulfamethoxazole and ampicillin.
- Has undergone a previous hysterectomy defined as removal of the entire uterus or will have a hysterectomy as part of their initial cervical cancer therapy. NOTE: Women who have had a partial/subtotal hysterectomy are eligible to participate in the study
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02853604
Locations
Show 117 study locations
Sponsors and Collaborators
Advaxis, Inc.
Gynecologic Oncology Group
Study Documents (Full-Text)
Documents provided by Advaxis, Inc.:
Documents provided by Advaxis, Inc.:
Study Protocol and Statistical Analysis Plan [PDF] December 7, 2020
| Responsible Party: | Advaxis, Inc. |
| ClinicalTrials.gov Identifier: | NCT02853604 |
| Other Study ID Numbers: |
ADXS001-02 2015-004844-20 ( EudraCT Number ) |
| First Posted: | August 3, 2016 Key Record Dates |
| Results First Posted: | March 14, 2023 |
| Last Update Posted: | March 14, 2023 |
| Last Verified: | February 2023 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Additional relevant MeSH terms:
|
Uterine Cervical Neoplasms Uterine Neoplasms Genital Neoplasms, Female Urogenital Neoplasms |
Neoplasms by Site Neoplasms Uterine Cervical Diseases Uterine Diseases |